XML 155 R98.htm IDEA: XBRL DOCUMENT v3.25.0.1
Principal changes in the scope of consolidation in 2023 - Additional Information (Details)
$ / shares in Units, € in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2024
EUR (€)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
EUR (€)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
EUR (€)
May 30, 2024
USD ($)
$ / shares
Sep. 29, 2023
EUR (€)
Sep. 29, 2023
USD ($)
Apr. 27, 2023
USD ($)
Mar. 13, 2023
USD ($)
$ / shares
Disclosure of detailed information about business combination [line items]                    
Net cash flow on acquisition | € [1] € 1,901   € 2,535 [2]   € 987 [2]          
Goodwill, tax deductible period     15 years 15 years            
Other intangible assets | € € 22,629   € 24,319   € 21,640          
Assets Acquisition                    
Disclosure of detailed information about business combination [line items]                    
Consideration transferred, acquisition-date fair value           $ 2,035.0        
Net cash flow on acquisition   $ 2,035.0                
Other intangible assets           $ 1,885.0        
Cash payment per non-transferable contingent value right (in USD per share) | $ / shares           $ 5.00        
Contingent consideration recognised as of acquisition date           $ 300.0        
Provention Bio, Inc                    
Disclosure of detailed information about business combination [line items]                    
Purchase price per share (in euro/usd per share) | $ / shares                   $ 25
Cash transferred                   $ 2,800.0
Equity interest in acquiree held before acquisition date                   $ 68.0
Consideration transferred, acquisition-date fair value                 $ 2,806.0  
Net cash flow on acquisition       $ 2,722.0            
Other intangible assets                 $ 2,810.0  
QRIB Intermediate Holding                    
Disclosure of detailed information about business combination [line items]                    
Consideration transferred, acquisition-date fair value             € 1,343 $ 1,419.0    
Identifiable intangible assets recognised as of acquisition date | €             774      
Goodwill recognised as of acquisition date | €             € 484      
[1] This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For 2024,
it includes the net cash outflow relating to the acquisition of Inhibrx, Inc. (see Note D.1..1). For 2023, it includes the net cash outflow on the acquisitions of
Provention Bio (see Note D.1.). For 2022, it includes the net cash outflow on the acquisition of Amunix (see Note D.1.)
[2] Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations).